Evidence map›Paper›PMID 39649079›Full record

ArticleBMJ neurology open2024

Assessment of axonal injury in multiple sclerosis: combined analysis of serum light-chain neurofilaments and diffusion tensor imaging.

Milad Jalilian, Mohammadreza Elhaie, Mohammadreza Sharifi, Iraj Abedi

Abstract read
In one paragraph

Article in BMJ neurology open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Milad JalilianDepartment of Neuroscience and Addiction Studies, Tehran University of Medical Sciences, Tehran, Iran (the Islamic Republic of).
Mohammadreza ElhaieDepartment of Medical Physics, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran (the Islamic Republic of).ORCID 0009-0007-1186-353X
Mohammadreza SharifiDepartment of Genetics and Molecular Biology, Isfahan University of Medical Sciences, Isfahan, Iran (the Islamic Republic of).
Iraj AbediDepartment of Medical Physics, Isfahan University of Medical Sciences, Isfahan, Iran (the Islamic Republic of).

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Multiple sclerosis (MS) is a chronic neuroinflammatory condition characterised by demyelination and axonal damage in the central nervous system. Diffusion tensor imaging (DTI) enables non-invasive investigation of microstructural white matter alterations, while serum neurofilament light chain (NFL) holds promise as a fluid biomarker of axonal injury. Objectives: To use DTI and serum NFL measurements to evaluate white matter pathology in patients with MS and explore the relationship between in vivo imaging and biochemical indicators of axonal damage. Methods: 41 patients with relapse-remitting MS and 41 age-matched healthy controls underwent brain MRI including DTI acquisition. Serum samples were analysed for NFL concentrations using ELISA. Region of interest analysis was conducted to derive DTI metrics including fractional anisotropy, mean diffusivity, axial diffusivity and radial diffusivity. Correlational analyses were used to explore the associations between the imaging and biochemical indices. Results: Patients exhibited significantly elevated serum NFL levels and altered DTI metrics compared with controls, indicative of axonal/myelin pathology. DTI parameters were positively correlated with serum NFL concentration (p value<0.0001). Visual analogue scale scores demonstrated a significant positive relationship between DTI metrics and NFL, validating their potential as radiological and fluid-based markers of symptom severity. Conclusions: Combined DTI and serum NFL measurements may enhance the evaluation of axonal injury in MS by providing complementary in vivo and biochemical perspectives. The corresponding changes observed between the modalities support their utility as non-invasive biomarkers reflecting pathophysiological processes and clinical status in MS. Larger validation cohorts are needed to determine the clinical applicability.

Indexed as

MRIMULTIPLE SCLEROSISNEUROPATHY

Identifiers

PMID39649079
PMCPMC11624819

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.